Member Info for chester18

No matter what any clandestine forces attempt or any mischievous manipulation is concocted the share price is going to keep on rising towards the MRE.

At that point if Newcrest say that the minimum gold in the ground is 10m or 12.5m ounces every institution not already on board will be banging on the door.

That MRE is a bankable resource, its definitely there in the ground with no doubts so how you going to short that?

Chester.

GH has a lot of skin in the game, he's been round the block a few times and doesn't come across as a mug. Also, I'm sure he won't countenance letting any dark arts masters into the inner circle.

Chester.

Dixie6789

Now is probably the best time to hold. After the open offer is complete as long as its classed as 'Over Subscribed' there is a very good chance that the share price will rise just on the positive sentiment. Also we are now in the realms of pivitol news, which can happen at anytime because there are a number of fronts all happening simultaneously.

So I say hold on tight as you may just see your 14.2p arrive again and then due to the details that got us back to that price it could be quickly surpassed.

ATB

Chester .

Morning GrizzlyB

It looks to me that the major shareholders realised that the CTX needs many £millions and is a large workload for the smallish numbers at Reneuron, so its temporarily suspended in the USA.

The journey so far on the Retinitus Pigmentosa has been a model trial. The results are excellent by any standard of measurement, it's well tolerated with no real side effects other than the surgery issues which they can negate by being stricter on the enrollment criteria and very importantly the positive improvement, lasts.
Well 18 months so far.

Considering the values put on the the Gene Therapy for only 2 to 3% of RP patients, consider that our approach could reach 90%. So what value will that be, many £billions ??

I can't see RP failing but we may need an injection of cash prior to the data required to do a mahoosive deal.

Chester.

Hi Attrick and GrizzlyB

I agree with both of your posts and so do the main Institutional Investors who have guided the company to favour both RP / Exosomes and park the CTX programme with the aim to do partnership deals in jurisdictions outside China and Hong Kong which is covered by Fosun.

The £12.6m in the bank should see the company well until this time next year and that will be about the earliest time for a large Pharma deal for the RP in the USA +/- Europe.

So we need some funds to come in from somewhere else, I was hoping for an upfront loaded deal on the Exosomes but we now know that if it happens it will be a minimum of 6 months. All this being said, RENEs technologies are extremely valuable so let's not rule out 'left field' completely.

Chester.

If its from the placing then they have cleared £20k profit.

Chester.

Hi Clivealive

I suggest you read through the Silence Therapeutics RNS dated 20th June 2020.

Main point is that they have £52m in cash and will be paid a further £40m by next May all from their signed deal with AstraZeneca.
In that deal AstraZeneca also bought SLN shares.

So 'Chalk and Cheese'.

When RENE sign a deal with upfront payments of £60m I would expect the SP to be higher than SLN's.

Meanwhile we have been told that it will be six months until an Exosomes deal is inked, that Fosun milestones in the region of £2m will be in the next 2 years dependant on Fosun reaching approvals in China.

What we don't know is how close we are to signing further deals for CTX and the RP programme. The share price is retracting due to the lack of any site of commercial activity in the next six months.

This will not stop me topping up as and when I can because the RP platform is so valuable that when they reach the end of Phase2 I would expect a major biotech company to move in.

Chester.

It looks like the mention of six months before the facilities come on line is scaring off anyone who only bought the placing to make a quick buck.

As there are so many shares in un-sticky hands it will take a while before a fair chunk are in the hands of long term investors.

This is a process that can only be helped by news from the company and todays news is a good start.

Chester

This is the first positive news although very much expected it is a real step forward in the building of investor confidence. The share price should react an equally positive way.

Chester.

Hi Sonnets

The predicted turnover for 2020 is around £16m ish. They have in the past made a good margin around 60%. In the 2019 figures they turned over £13m, if my memory serves me right, and made a £7m loss. So if they achieve their predicted turnover they may lose £4m less the monies in the grants.

So don't despair just yet, we need to get to a point where the company fills in some of those blanks.

For instance, how are sales going, how soon are they aiming to fit out the second facility, who is this Global Healthcare Provider and when does that contract begin to affect the manufacturing and profits.

When we know some more details we can then decide to despair or not ...... : )

Chester.

Hi KonarA

I fully accept your frustration as I wish we were a lot further down the road after all this time waiting for another new dawn.

Maybe I'm too accommodating but I do not hold the BOD responsible for all the delays with the SCIB1 trial.

They selected the Electroploration device as it was a very good way of inserting SCIB1 and making sure it was taken up by the muscle cells. The Ichor device used was a first generation or prototype but in the first trial it worked fantastically. When we submitted for this Combi trial it was Ichors modifictions that the FDA rejected.
Now we have CV-19 stopping the progress.

So that's the only difference between us I am very confident we have a committed, capable and diligent BOD.

Chester.

It's all about the Market Capitalization.

8.2p is £574 million that's a long ways ahead.

Once TRX hits gross sales in the region of £25m to £30m that will mean the company is past breakeven. The MCap will then reflect the company's future prospects and may reach £70m which is 1p per share.

My target for year end 2021 turnover is minimum £24m that's why I expect the share price to be double or treble this time next year. No bank or investment company will offer you that rate of interest. TRX now have the cash to make that happen.

Chester.

I know it was cheeky of me to ask ...

Chester.

Hi Mushroomkid

Just for fun while we wait the Big'un could you estimate the combined GGP worth of the gig......... : )

Chester.

We all knew that a placing was more than likely.
Scancell needs the money to progress, so whats the issue !

I factored in the possibility of 300m shares at 3.5p and still saw that as positive for the long term good of both company and shareholders.

Once our platforms reach validation and valuation the SP / Market Cap will be many times todays share price.

So this RNS is really good news.

Chester.

Thanks Moljen

I'm not thinking if selling just trying to understand how it works.
For my part I'm going to subscribe to everything I'm entitled to plus ask for upto another 1/2 million share in the excess. That's if there are any left to buy.

Chester.

Hi researcher1

What is the date you need to have a holding I didn't notice it in the RNS ?

Chester.

Morning GF123

I've always railed against the doomongers and the plain old miserable oiks on this board.

They always predicted 3p and Scancell never amounting to much.

Well their ship has truly sailed and if you listen closely you will hear the gnashing and grinding of teeth.

I think, for what it's worth, we should now leave them to stew. We don't need to exact our frustration on them just let their attempts at getting a reaction go unanswered as that will be even more pain on them.

Plus the board can be back to worth reading all about the future prospects and delivery of the science.

I hope you agree

ATB

Chester.

Thank you Moljen for speaking up against these classroom rants.

I took one look at the tone of the posts earlier today and deleted Scancell LSE from my bookmarks. Its now a bind to try and search for the decent intelligent and informative posts. If it persists I for one will call this board a basket case and stop reading, following or posting.

Some days its just a grind.

Chester.

I was really hoping for pivitol news on the original Exosomes collaboration but it will be another 6 months at least before a decision can be made. On the Good news front we can see that the next 12 to 18 months is going to see Reneuron leave the R&D space and become a fully fledged Biotechnology company, complete with fully validated and very valuable platforms.

What could the SP be in late 2023 ?

I know its jam tomorrow but this is cutting edge tech that will begin to change many aspects of medical treatments and the way we start to repair the un-repairable.

Chester.